Stablepharma is delighted to announce that we have been selected as to be part of Innovate UK’s prestigious Scaleup Programme, in recognition of our potential to grow exponentially and scale globally. The Scaleup Programme is provided by Innovate UK Business Growth, the innovation agency’s national business growth and scaling service, which supports businesses to grow […]
Read More
Stablepharma Ltd in collaboration with their leading global CDMO partner have achieved a significant milestone in the GMP manufacture of their lead candidate, fridge-free Tetanus Diphtheria vaccine (SPVX02), based on StablevaX™ technology. Stablepharma have reported the successful manufacture and analytical testing of over 10,000 vials (doses) of SPVX02 under GMP conditions, in Monza, Italy and […]
Read More
Stablepharma is delighted to welcome Martin Sastre Gallardo to the R&D team at Qube Technology Park in Madrid. As Research Scientist, he will work closely with Lorena Carmona, Senior Scientist, who is leading the RNA-LNP thermostabilisation programme in Spain. Martin joins Stablepharma after working for several years as a Senior Research Scientist at the National […]
Read More
Stablepharma reveals 12 months stability data for our second fridge-free vaccine, SPVX06 for Tetanus. This significant milestone reinforces Stablepharma’s ability to demonstrate the robustness of our platform of reformulated vaccines, including SPVX02 for the prevention of Tetanus diphtheria. In-vivo challenge studies demonstrated that SPVX06 maintains its potency, providing comprehensive protection while effectively stimulating the immune […]
Read More
As Stablepharma continues to expand the teams in both London and Madrid, CEO & Executive Director, Ozgur Tuncer was delighted to announce that Stephanie Maley (of Factotum) has joined the executive team of Stablepharma in the role of Chief People Officer. Stephanie started her career in the finance industry and then moved into HR Consultancy. […]
Read More
Stablepharma is delighted to welcome Dr Kenny Simmen to the Advisory Board, who brings over 30 years pharmaceutical expertise in R&D with a successful track record in drug discovery and external innovation. Dr Simmen will work closely with the science and commercial teams to support further R&D deals and evaluate suitable vaccine candidates that will […]
Read More
click here to read full article
Read More
The United Kingdom is a hub for innovative startups and companies in the realm of impact investing, a variety of investing that seeks to generate both financial return and social or environmental good. Impact investing is fast gaining traction as we move towards a more responsible and sustainable way of doing business. It aligns money […]
Read More